米卡芬净在儿科免疫功能低下侵袭性真菌感染患者中的疗效。
Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.
作者信息
Hashii Yoshiko, Kusuki Shigenori, Takizawa Sachiko, Tokimasa Sadao, Ohta Hideaki, Hara Junichi, Ozono Keiichi
机构信息
Department of Developmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Pediatrics, National Hospital Organization Osaka National Hospital, Osaka, Japan.
出版信息
Pediatr Int. 2014 Dec;56(6):834-837. doi: 10.1111/ped.12356. Epub 2014 Sep 17.
BACKGROUND
Micafungin, an antifungal echinocandin, has been indicated for pediatric patients with invasive fungal infection (IFI) in Japan and Europe. Its efficacy in immunocompromised pediatric patients with IFI, however, has not been fully investigated.
METHODS
The safety and efficacy of micafungin as an antifungal therapy were analyzed in nine consecutive severe immunocompromised patients with IFI.
RESULTS
Three patients with proven or probable Candida infections had complete response to micafungin therapy. Of the other six patients with proven, probable or possible Aspergillus infection, four had complete response and one had partial response to micafungin treatment. No severe adverse events were observed.
CONCLUSIONS
In this small series, micafungin was effective for IFI caused by both Candida and Aspergillus species and no severe adverse events were observed in these immunocompromised patients.
背景
米卡芬净是一种抗真菌棘白菌素，在日本和欧洲已被批准用于侵袭性真菌感染（IFI）的儿科患者。然而，其在免疫功能低下的IFI儿科患者中的疗效尚未得到充分研究。
方法
对9例连续的严重免疫功能低下的IFI患者使用米卡芬净作为抗真菌治疗的安全性和疗效进行分析。
结果
3例确诊或疑似念珠菌感染的患者对米卡芬净治疗完全缓解。在其他6例确诊、疑似或可能为曲霉菌感染的患者中，4例对米卡芬净治疗完全缓解，1例部分缓解。未观察到严重不良事件。
结论
在这个小系列研究中，米卡芬净对念珠菌和曲霉菌引起的IFI有效，且在这些免疫功能低下的患者中未观察到严重不良事件。
Zotero 插件